Spots Global Cancer Trial Database for tmb
Every month we try and update this database with for tmb cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | NCT03911557 | Tumor, Solid | Durvalumab and ... | 18 Years - | University of Kentucky |